321 related articles for article (PubMed ID: 25989609)
41. Treatment of rheumatoid arthritis with etanercept with reference to disease-modifying anti-rheumatic drugs: long-term safety and survival using prospective, observational data.
Morgan CL; Emery P; Porter D; Reynolds A; Young A; Boyd H; Poole CD; Currie CJ
Rheumatology (Oxford); 2014 Jan; 53(1):186-94. PubMed ID: 24140761
[TBL] [Abstract][Full Text] [Related]
42. Factors associated with treatment response to etanercept in juvenile idiopathic arthritis.
Otten MH; Prince FH; Armbrust W; ten Cate R; Hoppenreijs EP; Twilt M; Koopman-Keemink Y; Gorter SL; Dolman KM; Swart JF; van den Berg JM; Wulffraat NM; van Rossum MA; van Suijlekom-Smit LW
JAMA; 2011 Dec; 306(21):2340-7. PubMed ID: 22056397
[TBL] [Abstract][Full Text] [Related]
43. Proinflammatory cytokines in monitoring the course of disease and effectiveness of treatment with etanercept (ETN) of children with oligo- and polyarticular juvenile idiopathic arthritis (JIA).
Kaminiarczyk-Pyzalka D; Adamczak K; Mikos H; Klimecka I; Moczko J; Niedziela M
Clin Lab; 2014; 60(9):1481-90. PubMed ID: 25291944
[TBL] [Abstract][Full Text] [Related]
44. Safety and efficacy of long-term etanercept in the treatment of methotrexate-refractory polyarticular-course juvenile idiopathic arthritis in Japan.
Mori M; Takei S; Imagawa T; Imanaka H; Nerome Y; Higuchi R; Kawano Y; Yokota S; Sugiyama N; Yuasa H; Fletcher T; Wajdula JS
Mod Rheumatol; 2012 Sep; 22(5):720-6. PubMed ID: 22212889
[TBL] [Abstract][Full Text] [Related]
45. Drug survival of the first and second course of anti-tumour necrosis factor agents in juvenile idiopathic arthritis.
Tynjälä P; Vähäsalo P; Honkanen V; Lahdenne P
Ann Rheum Dis; 2009 Apr; 68(4):552-7. PubMed ID: 18467515
[TBL] [Abstract][Full Text] [Related]
46. Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis.
Wallace CA; Giannini EH; Spalding SJ; Hashkes PJ; O'Neil KM; Zeft AS; Szer IS; Ringold S; Brunner HI; Schanberg LE; Sundel RP; Milojevic D; Punaro MG; Chira P; Gottlieb BS; Higgins GC; Ilowite NT; Kimura Y; Hamilton S; Johnson A; Huang B; Lovell DJ;
Arthritis Rheum; 2012 Jun; 64(6):2012-21. PubMed ID: 22183975
[TBL] [Abstract][Full Text] [Related]
47. Phase III, multicentre, double-blind, randomised, parallel-group study to evaluate the similarities between LBEC0101 and etanercept reference product in terms of efficacy and safety in patients with active rheumatoid arthritis inadequately responding to methotrexate.
Matsuno H; Tomomitsu M; Hagino A; Shin S; Lee J; Song YW
Ann Rheum Dis; 2018 Apr; 77(4):488-494. PubMed ID: 29259050
[TBL] [Abstract][Full Text] [Related]
48. Switching the therapy from etanercept to infliximab in a child with rheumatoid factor positive polyarticular juvenile idiopathic arthritis.
Nerome Y; Imanaka H; Nonaka Y; Takei S
Mod Rheumatol; 2007; 17(6):526-8. PubMed ID: 18084710
[TBL] [Abstract][Full Text] [Related]
49. Improvement of functional ability in children with juvenile idiopathic arthritis by treatment with etanercept.
Halbig M; Horneff G
Rheumatol Int; 2009 Dec; 30(2):229-38. PubMed ID: 19449011
[TBL] [Abstract][Full Text] [Related]
50. Safety and efficacy of etanercept in a cohort of patients with juvenile idiopathic arthritis under 4 years of age.
Bracaglia C; Buonuomo PS; Tozzi AE; Pardeo M; Nicolai R; Campana A; Insalaco A; Cortis E; DE Benedetti F
J Rheumatol; 2012 Jun; 39(6):1287-90. PubMed ID: 22589254
[TBL] [Abstract][Full Text] [Related]
51. Infection risk in patients with rheumatoid arthritis treated with etanercept or adalimumab.
Chiang YC; Kuo LN; Yen YH; Tang CH; Chen HY
Comput Methods Programs Biomed; 2014 Oct; 116(3):319-27. PubMed ID: 25022467
[TBL] [Abstract][Full Text] [Related]
52. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register.
Dixon WG; Watson K; Lunt M; Hyrich KL; Silman AJ; Symmons DP;
Arthritis Rheum; 2006 Aug; 54(8):2368-76. PubMed ID: 16868999
[TBL] [Abstract][Full Text] [Related]
53. Short and long-term immunogenicity and safety following the 23-valent polysaccharide pneumococcal vaccine in juvenile idiopathic arthritis patients under conventional DMARDs with or without anti-TNF therapy.
Aikawa NE; França IL; Ribeiro AC; Sallum AM; Bonfa E; Silva CA
Vaccine; 2015 Jan; 33(5):604-9. PubMed ID: 25554240
[TBL] [Abstract][Full Text] [Related]
54. Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment.
Beukelman T; Xie F; Chen L; Baddley JW; Delzell E; Grijalva CG; Lewis JD; Ouellet-Hellstrom R; Patkar NM; Saag KG; Winthrop KL; Curtis JR;
Arthritis Rheum; 2012 Aug; 64(8):2773-80. PubMed ID: 22569881
[TBL] [Abstract][Full Text] [Related]
55. Patient-reported outcomes improve with etanercept plus methotrexate in active early rheumatoid arthritis and the improvement is strongly associated with remission: the COMET trial.
Kekow J; Moots RJ; Emery P; Durez P; Koenig A; Singh A; Pedersen R; Robertson D; Freundlich B; Sato R
Ann Rheum Dis; 2010 Jan; 69(1):222-5. PubMed ID: 19293160
[TBL] [Abstract][Full Text] [Related]
56. Efficacy and safety of etanercept in patients with the enthesitis-related arthritis category of juvenile idiopathic arthritis: results from a phase III randomized, double-blind study.
Horneff G; Foeldvari I; Minden K; Trauzeddel R; Kümmerle-Deschner JB; Tenbrock K; Ganser G; Huppertz HI
Arthritis Rheumatol; 2015 May; 67(8):2240-9. PubMed ID: 25891010
[TBL] [Abstract][Full Text] [Related]
57. Dynamics of concomitant therapy in children with juvenile idiopathic arthritis treated with etanercept and methotrexate.
Alexeeva E; Dvoryakovskaya T; Denisova R; Sleptsova T; Isaeva K; Chomahidze A; Fetisova A; Mamutova A; Alshevskaya A; Gladkikh V; Moskalev A
Pediatr Neonatol; 2019 Oct; 60(5):549-555. PubMed ID: 30885783
[TBL] [Abstract][Full Text] [Related]
58. A combination of etanercept and methotrexate for the treatment of refractory juvenile idiopathic arthritis: a pilot study.
Schmeling H; Mathony K; John V; Keysser G; Burdach S; Horneff G
Ann Rheum Dis; 2001 Apr; 60(4):410-2. PubMed ID: 11247875
[TBL] [Abstract][Full Text] [Related]
59. Inflammatory Bowel Disease in Juvenile Idiopathic Arthritis Patients Treated with Biologics.
Barthel D; Ganser G; Kuester RM; Onken N; Minden K; Girschick HJ; Hospach A; Horneff G
J Rheumatol; 2015 Nov; 42(11):2160-5. PubMed ID: 26373564
[TBL] [Abstract][Full Text] [Related]
60. Treatment persistence with adalimumab, etanercept, or infliximab in combination with methotrexate and the effects on health care costs in patients with rheumatoid arthritis.
Tang B; Rahman M; Waters HC; Callegari P
Clin Ther; 2008 Jul; 30(7):1375-84. PubMed ID: 18691998
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
